TCF7 and prostate carcinoma: In addition, our clinical data showed that miR-34a expression is significantly higher in prostate cancer patients with a low TCF7 expression (Figure 3E and 3F, Figure 4A and 4B), and significantly lower in tumors expressing a high nuclear level of TCF7 (Figure 4C).